Quick Answer
Cabaletta Bio, Inc. reported Research And Development Expense of $142.67 million for the year ending 2025.
- Cabaletta Bio, Inc. showed an increase of +46.8% in Research And Development Expense from 2024 to 2025.
- This data is from Cabaletta Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $2.59 million | Q1 2019: $2.76 million | Q2 2019: $2.66 million | Q3 2019: $3.22 million | Q1 2020: $4.62 million | Q2 2020: $5.33 million | Q3 2020: $5.65 million | Q1 2021: $6.56 million | Q2 2021: $7.85 million | Q3 2021: $8.17 million | Q1 2022: $9.17 million | Q2 2022: $9.51 million | Q3 2022: $8.22 million | Q1 2023: $12.44 million | Q2 2023: $11.80 million | Q3 2023: $13.79 million | Q1 2024: $21.95 million | Q2 2024: $23.43 million | Q3 2024: $26.29 million | Q1 2025: $29.02 million | Q2 2025: $37.64 million | Q3 2025: $39.82 million.
- Over the full 8 years of available data (2018 to 2025), Cabaletta Bio, Inc.'s Research And Development Expense has grown by 3,094.0%.
- Historical annual values: Fiscal year 2025: $142.67 million | Fiscal year 2024: $97.20 million | Fiscal year 2023: $55.42 million | Fiscal year 2022: $39.30 million | Fiscal year 2021: $32.49 million | Fiscal year 2020: $21.38 million | Fiscal year 2019: $11.67 million | Fiscal year 2018: $4.47 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: